Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
info@inspirna.com

Michael Ginder

Inspirna

Michael is currently a research analyst at Sands Capital, a leading growth-oriented investment firm. Since joining in 2011, he has invested in life sciences businesses across the private and public markets, with a primary focus on therapeutics. In addition to Inspirna, he also serves on the board of Prilenia Therapeutics. Michael earned a B.S. in Commerce from the University of Virginia in 2011 and has been a CFA charterholder since 2015.